Search
-
NewEADV 2025: Almirall advances skin science and leads innovation for holistic patient care i...
Almirall stands out at the EADV 2025 Congress with 44 scientific presentations and new data from its portfolio in atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa
-
NewORYZON strengthens patent portfolio for iadademstat and vafidemstat with new Decisions to ...
Oryzon Genomics S.A., a clinical-stage biopharmaceutical company and European leader in epigenetics, has strengthened its global intellectual property position after receiving new patent grant
-
NewBCN HEALTH presents new analyses on hepatitis delta vs. hepatitis B healthcare costs in Sp...
BCN HEALTH participated in the European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2025), which took place in May in Amsterdam, the Netherlands. Two new
-
NewFarmadosis, a benchmark in pharmaceutical automation and safe medication management
With more than 20 years of experience, the Spanish company develops automation and digital solutions that enhance patient safety, optimize pharmaceutical processes, and improve the efficiency of
-
NewWorld’s first foal born through maternal spindle transfer, an advanced assisted reproducti...
Embryotools, a biotechnology centre based at the Parc Científic de Barcelona (PCB), has achieved a new milestone in the field of assisted reproduction with the birth of the world’s first foal
-
NewBiohope presents the results of the BIOTRAIM study at the World Transplant Congress 2025: ...
Immunobiogram® is a test that measures in vitro the sensitivity (response) of each patient's immune system cells to immunosuppressive drugs, with the aim of facilitating the personalization of
-
New#BIOSPAIN2025 | “Abioinnova has decided to support BIOSPAIN 2025, the leading meeting of t...
We interviewed Pedro Martínez Córdoba, Councillor for Economic Promotion of Salamanca City Council, Gold Sponsor of BIOSPAIN 2025, to analyze the Abioinnova initiative.
-
NewSepsis causes up to 20,000 annual deaths in Spain: Biotechnology is revolutionizing early ...
Viva In Vitro, an AseBio member, has developed VIVA-ELISA, a biotechnology tool that rapidly detects activation of the NLRP3 inflammasome, enabling evaluation of the immune system’s ability to respond
-
NewLife Sciences Strategy: Europe’s commitment to remain a global leader in health
Growing investment in R&D, eliminating unnecessary bureaucratic hurdles, and creating governance structures of its own are the main actions the European Union will undertake to reinforce its
-
New#BIOSPAIN2025 | “Hosting international events and participating as sponsors in key gatheri...
We interviewed Román Rodríguez González, Regional Minister of Education, Science, Universities and Vocational Training of the Xunta de Galicia, Gold Sponsor, to analyze the Xunta’s commitment to
-
NewAsabys Partners Leads €10 Million Extension of SafeHeal’s Oversubscribed Series C Financin...
Asabys joins SafeHeal’s global investor syndicate, which includes Sofinnova, Solar Eclipse and a Leading Multinational Life Sciences Corporation, bringing additional resources and strategic expertise
-
NewCONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X ...
CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data
-
NewBIOSPAIN becomes an annual event, consolidating its leadership as a driving force of the S...
The host city for BIOSPAIN 2026 will be announced during the official events at BIOSPAIN 2025, while Barcelona is confirmed as the venue for the 2027 and 2029 editions.
-
NewBiotechnology and Regenerative Agriculture: The alliance for the future of farming
Regenerative Agriculture aims to restore agricultural ecosystems through healthier soils, resilient crops, and systems that capture carbon, generate income, and address the challenges of climate
-
New#BIOSPAIN2025 | HIPRA Biotech Services: strengthening Europe’s strategic autonomy in biote...
Eduard Viladesau, Managing Director of HIPRA Biotech Services, Gold Sponsor of BIOSPAIN 2025, analyzes the role of this business unit within HIPRA’s global strategy.
-
NewNatac transformed over 9,000 tons of biomass into high-value ingredients
This is reflected in its 2024 Sustainability Report, which reviews the company's main ESG milestones
-
NewIntegra Therapeutics secures €10.7 million investment round to advance development of FiCA...
The investment combines funds from new investors like the EIC Fund (European Commission) and CDTI Innvierte (Government of Spain) and current investors (AdBio, Columbus, Invivo and Takeda).
-
NewThe microbiota revolution
The study of the microbiota has gone from a focus limited to digestion to become a pillar of preventive and personalised medicine, opening up new therapeutic opportunities in multiple areas of health.
-
NewTalking Science in Summer: Bionet is making bioprocessing easier to understand
Bioprocessing is full of complex terms and concepts that can be difficult to digest. This summer, Bionet launched Talking Science in Summer: a series of short comics that break down key ideas into
-
New#BIOSPAIN2025 | “It represents an opportunity to share knowledge, explore new avenues of c...
José María Giménez Arnau, Chief Scientific & Medical Officer at ESTEVE, Gold Sponsor of BIOSPAIN 2025, shares the company’s commitment to innovation applied to highly specialized medicine.
-
NewSPEEDCELL, the new European project led by HIPRA, aims to reduce vaccine and biologics dev...
With a duration of 4 years, this EU4Health program project aims to contribute to strengthening global health response capacity in international emergency situations.